AstraZeneca’s new cancer drug manufacturing facility to create 800 jobs in Singapore

The facility is set to be operational by 2029.

AstraZeneca plans to hire over 800 in Singapore for engineering, quality, technical services, and supply chain roles at its new antibody drug conjugates (ADCs) manufacturing facility set to open by 2029.

The US$1.5b facility has commenced construction at a 58-acre site in Tuas South. It will produce ADCs that deliver potent cancer-killing agents directly to cancer cells via targeted antibodies.

The facility marks AstraZeneca’s first fully integrated end-to-end ADC production site globally. The production of ADCs includes antibody production, synthesis of the chemotherapy drug and linker, drug-linker conjugation to the antibody, and filling the completed ADC substance into vials.

“This greenfield investment will significantly enhance Singapore's growing biopharmaceutical sector, particularly in precision medicine development and manufacturing for improved healthcare outcomes,” Jacqueline Poh, managing director of the Singapore Economic Development Board (EDB) said.